XBiotech, Inc. (XBIT)
1.91
-0.06
(-3.05%)
USD |
NASDAQ |
Oct 23, 16:00
1.91
0.00 (0.00%)
After-Hours: 20:00
XBiotech Net Income (Quarterly) : -6.728M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.728M |
| March 31, 2026 | -5.505M |
| December 31, 2025 | -26.89M |
| September 30, 2025 | -6.008M |
| June 30, 2025 | -1.756M |
| March 31, 2025 | -10.88M |
| December 31, 2024 | -10.51M |
| September 30, 2024 | -5.015M |
| June 30, 2024 | -13.01M |
| March 31, 2024 | -10.00M |
| December 31, 2023 | -4.635M |
| September 30, 2023 | -7.364M |
| June 30, 2023 | -8.742M |
| March 31, 2023 | -3.816M |
| December 31, 2022 | -3.203M |
| September 30, 2022 | -12.66M |
| June 30, 2022 | -11.64M |
| March 31, 2022 | -5.395M |
| December 31, 2021 | -6.467M |
| September 30, 2021 | -3.261M |
| June 30, 2021 | -5.118M |
| March 31, 2021 | -2.568M |
| December 31, 2020 | -1.838M |
| September 30, 2020 | -2.526M |
| Date | Value |
|---|---|
| June 30, 2020 | -6.844M |
| March 31, 2020 | -0.014M |
| December 31, 2019 | 686.50M |
| September 30, 2019 | -6.15M |
| June 30, 2019 | -5.852M |
| March 31, 2019 | -5.864M |
| December 31, 2018 | -6.111M |
| September 30, 2018 | -5.051M |
| June 30, 2018 | -5.907M |
| March 31, 2018 | -4.069M |
| December 31, 2017 | -7.249M |
| September 30, 2017 | -6.205M |
| June 30, 2017 | -9.133M |
| March 31, 2017 | -10.56M |
| December 31, 2016 | -16.40M |
| September 30, 2016 | -12.48M |
| June 30, 2016 | -13.62M |
| March 31, 2016 | -10.26M |
| December 31, 2015 | -11.89M |
| September 30, 2015 | -10.74M |
| June 30, 2015 | -6.744M |
| March 31, 2015 | -8.114M |
| December 31, 2014 | -5.889M |
| December 31, 2013 | -2.487M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.728M |
| EPS Diluted (Quarterly) | -0.2207 |
| Enterprise Value | -49.47M |
| Earnings Yield | -77.51% |
| Normalized Earnings Yield | -77.51 |